<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438048</url>
  </required_header>
  <id_info>
    <org_study_id>CAVK-130108245-1</org_study_id>
    <nct_id>NCT00438048</nct_id>
  </id_info>
  <brief_title>A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment</brief_title>
  <official_title>Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Formulario MAgistral Farmacias Ahumada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the safetyness and efficacy of pilocarpine
      drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by
      SS in a multicenter, doubleblind, controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:

      Xerostomy treatment in patients with Sjogren's syndrome in Chile :A double blind control
      trial comparing orally Pilocarpine drops and Artificial Saliva

      Authors:

      Cristian Vera Kellet, Mirtha Cifuentes Mutinelli. Affiliations: Pontificia Universidad
      Catolica de Chile

      BACKGROUND Sjogren's syndrome (SS) is characterized by diminished exocrine secretions with
      the resultant xerostomia and xerophthalmia due to slowly progressive infiltration of lacrimal
      and salivary glands by inflamatory cells.

      OBJECTIVE: To assess and compare the safetyness and efficacy of pilocarpine drops versus
      artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by SS in a
      multicenter, doubleblind, controlled trial.

      SUBJECTS AND METHODS After providing written informed consent, 72 patients with primary or
      secondary SS and clinically significant dry mouth and dry eyes will be randomized to receive
      either 5-mg pilocarpine drops, or artificial saliva 3 times daily for 12 weeks. Global
      evaluation and subjective responses of patients will be assessed by questionnaires with
      visual analog scales or categorical checkboxes. All patients will be submited to anxiety and
      psicological test before and after 12 weeks. Whole-mouth salivary flow and lacrimal flow will
      be measured using Schirmer test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess and compare the safetyness and efficacy of pilocarpine drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by SS in a multicenter, doubleblind, controlled trial.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine on a subjetive manner wich treatment is better fot patients.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Primary Sjogren</condition>
  <condition>Secondary Sjogren</condition>
  <condition>Xerostomia</condition>
  <arm_group>
    <arm_group_label>a,b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare Pilocarpine and Artificial saliva</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pilocarpine</intervention_name>
    <description>or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks</description>
    <arm_group_label>a,b</arm_group_label>
    <other_name>Artificial saliva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Saliva</intervention_name>
    <description>5ml 3 times daily</description>
    <arm_group_label>a,b</arm_group_label>
    <other_name>pilocarpine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patiens over 18 years, with primary or secondary Sjogren's Syndrome and xerostomia.

        Exclusion Criteria:

          -  Patiens with cardiac, pulmonary, renal, gastric diseases,

          -  Patients with diabetes, glaucoma, Multipleesclerosis,

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristian Vera-Kellet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UDA Dermatologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad Docente Asociada Dermatologia. Escuela de MEdicina Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA Jr, Walsh BT, Trivedi M, Goldlust B, Gallagher SC. Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study. J Clin Rheumatol. 2004 Aug;10(4):169-77.</citation>
    <PMID>17043506</PMID>
  </reference>
  <reference>
    <citation>Al-Hashimi I. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Drugs Aging. 2005;22(11):887-99. Review.</citation>
    <PMID>16323968</PMID>
  </reference>
  <reference>
    <citation>Masters KJ. Pilocarpine treatment of xerostomia induced by psychoactive medications. Am J Psychiatry. 2005 May;162(5):1023.</citation>
    <PMID>15863819</PMID>
  </reference>
  <reference>
    <citation>Götrick B, Akerman S, Ericson D, Torstenson R, Tobin G. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res. 2004 May;83(5):393-7.</citation>
    <PMID>15111631</PMID>
  </reference>
  <reference>
    <citation>Hendrickson RG, Morocco AP, Greenberg MI. Pilocarpine toxicity and the treatment of xerostomia. J Emerg Med. 2004 May;26(4):429-32.</citation>
    <PMID>15093850</PMID>
  </reference>
  <reference>
    <citation>Solans R, Bosch JA, Selva A, Simeón CP, Fonollosa V, Vilardell M. [Usefulness of oral pilocarpin therapy in the treatment of xerostomia and xerophthalmia in patients with primary Sjögren's syndrome]. Med Clin (Barc). 2004 Feb 28;122(7):253-5. Spanish.</citation>
    <PMID>15012873</PMID>
  </reference>
  <reference>
    <citation>Tsifetaki N, Kitsos G, Paschides CA, Alamanos Y, Eftaxias V, Voulgari PV, Psilas K, Drosos AA. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis. 2003 Dec;62(12):1204-7.</citation>
    <PMID>14644860</PMID>
  </reference>
  <results_reference>
    <citation>Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial. J Formos Med Assoc. 2006 Oct;105(10):796-803.</citation>
    <PMID>17000452</PMID>
  </results_reference>
  <results_reference>
    <citation>Brito-Zerón P, Ramos-Casals M, Nardi N, Font J. [Results of the treatment with oral pilocarpine in 100 patients with primary Sjögrens syndrome]. Med Clin (Barc). 2006 Apr 29;126(16):637. Spanish.</citation>
    <PMID>16759558</PMID>
  </results_reference>
  <results_reference>
    <citation>Aframian DJ, Helcer M, Livni D, Markitziu A. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis. 2006 May;12(3):297-300.</citation>
    <PMID>16700739</PMID>
  </results_reference>
  <results_reference>
    <citation>Aragona P, Di Pietro R, Spinella R, Mobrici M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome. Br J Ophthalmol. 2006 Feb;90(2):166-70.</citation>
    <PMID>16424527</PMID>
  </results_reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>May 21, 2008</last_update_submitted>
  <last_update_submitted_qc>May 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cristian Vera Kellet</name_title>
    <organization>Pontificia Universidad Católica de Chile</organization>
  </responsible_party>
  <keyword>Pilocarpine</keyword>
  <keyword>Artificial saliva</keyword>
  <keyword>Xerostomia</keyword>
  <keyword>Xerostomy</keyword>
  <keyword>Primary Sjogren</keyword>
  <keyword>Secondary Sjogren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

